Aclairo Pharma Dev. Group

Aclairo Pharmaceutical Development Group is a privately held, US-based regulatory and scientific consulting firm founded in 2004 and headquartered in Sterling, Virginia. The company operates as a service provider, offering deep expertise in non-clinical drug development and regulatory strategy, with a staff composed largely of ex-FDA supervisors and seasoned industry professionals. Its business model is centered on providing fee-for-service consulting, program management, and regulatory writing support, positioning it as a key partner for biopharma companies, particularly those developing novel therapeutics like cell and gene therapies. Aclairo is a revenue-generating entity that mitigates client risk through its regulatory insights and operational support.

Intellectual capital and methodology based on ex-FDA and industry expertise in non-clinical development (toxicology, DMPK, pathology) and regulatory strategy for drugs, biologics, and cell/gene therapies.

Competes with large, full-service CROs (e.g., IQVIA, Labcorp) that offer regulatory consulting, and other niche specialist consultancies founded by ex-regulators. Differentiation is based on deep, hands-on expertise of senior consultants, a focus on non-clinical/regulatory toxicology, and a high-touch service model.